Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurizio Lazzero

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Recent Patents on Cardiovascular Drug Discovery|January 7, 2011
Levosimendan: from basic science to clinical trialsAndrea Rognoni, Alessandro Lupi, Maurizio Lazzero, et al.
The Journal of Invasive Cardiology|April 9, 2011
Safety and efficacy of the new Angio-Seal Evolution™ closure device: a single-center experienceAlessandro Lupi, Maurizio Lazzero, Laura Plebani, et al.
Giornale Italiano Di Cardiologia (2006)|August 7, 2008
[Death after ST-elevation myocardial infarction in patients treated with fibrinolytic therapy, angioplasty, or conventional therapy. A post-mortem study to verify cardiac rupture as a cause of death]Gianluigi Fornaro, Maurizio Lazzero, Angela Giacalone, et al.
Cardiovascular & Hematological Agents in Medicinal Chemistry|May 18, 2011
Update on glycoprotein IIb/IIIa: role in primary coronary interventionAndrea Rognoni, Alessandro Lupi, Gioel Gabrio Secco, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 25, 2013
Intracoronary bivalirudin: a new way to appease the hostile thrombus?Alessandro Lupi, Italo Porto, Andrea Rognoni, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 22, 2010
Drug-eluting stents vs. bare metal stents in saphenous vein graft disease. Insights from a meta-analysis of 7,090 patientsAlessandro Lupi, Eliano Pio Navarese, Maurizio Lazzero, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|September 27, 2016
Pre-hospital ticagrelor in patients with ST-segment elevation myocardial infarction with long transport time to primary PCI facilityAlessandro Lupi, Alon Schaffer, Maurizio Lazzero, et al.
European Journal of Preventive Cardiology|November 16, 2012
Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patientsAlessandro Lupi, Andrea Rognoni, Gioel Gabrio Secco, et al.
Cardiovascular & Hematological Agents in Medicinal Chemistry|September 12, 2012
Pharmacological adjuvant therapies in primary coronary interventions: bivalirudinAlessandro Lupi, Andrea Rognoni, Chiara Cavallino, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 19, 2014
Below normal pre-procedural cardiac troponin I levels are associated with an adverse prognosis after percutaneous coronary interventionsAlessandro Lupi, Andrea Rognoni, Maurizio Lazzero, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Recent Patents on Cardiovascular Drug Discovery|January 7, 2011
Levosimendan: from basic science to clinical trialsAndrea Rognoni, Alessandro Lupi, Maurizio Lazzero, et al.
The Journal of Invasive Cardiology|April 9, 2011
Safety and efficacy of the new Angio-Seal Evolution™ closure device: a single-center experienceAlessandro Lupi, Maurizio Lazzero, Laura Plebani, et al.
Giornale Italiano Di Cardiologia (2006)|August 7, 2008
[Death after ST-elevation myocardial infarction in patients treated with fibrinolytic therapy, angioplasty, or conventional therapy. A post-mortem study to verify cardiac rupture as a cause of death]Gianluigi Fornaro, Maurizio Lazzero, Angela Giacalone, et al.
Cardiovascular & Hematological Agents in Medicinal Chemistry|May 18, 2011
Update on glycoprotein IIb/IIIa: role in primary coronary interventionAndrea Rognoni, Alessandro Lupi, Gioel Gabrio Secco, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 25, 2013
Intracoronary bivalirudin: a new way to appease the hostile thrombus?Alessandro Lupi, Italo Porto, Andrea Rognoni, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 22, 2010
Drug-eluting stents vs. bare metal stents in saphenous vein graft disease. Insights from a meta-analysis of 7,090 patientsAlessandro Lupi, Eliano Pio Navarese, Maurizio Lazzero, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|September 27, 2016
Pre-hospital ticagrelor in patients with ST-segment elevation myocardial infarction with long transport time to primary PCI facilityAlessandro Lupi, Alon Schaffer, Maurizio Lazzero, et al.
European Journal of Preventive Cardiology|November 16, 2012
Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patientsAlessandro Lupi, Andrea Rognoni, Gioel Gabrio Secco, et al.
Cardiovascular & Hematological Agents in Medicinal Chemistry|September 12, 2012
Pharmacological adjuvant therapies in primary coronary interventions: bivalirudinAlessandro Lupi, Andrea Rognoni, Chiara Cavallino, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 19, 2014
Below normal pre-procedural cardiac troponin I levels are associated with an adverse prognosis after percutaneous coronary interventionsAlessandro Lupi, Andrea Rognoni, Maurizio Lazzero, et al.
Pageof 2